78060-44-3 Usage
Uses
Used in Pharmaceutical Industry:
Pyrimidine, 2-(chloromethyl)-4-methyl(9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique reactivity allows for the creation of new drug molecules with potential therapeutic applications. The chloromethyl group can be utilized for further functionalization, enabling the attachment of different functional groups to enhance the pharmacological properties of the resulting compounds.
Used in Agrochemical Industry:
In the agrochemical industry, Pyrimidine, 2-(chloromethyl)-4-methyl(9CI) serves as a building block for the development of new agrochemicals. Its reactivity and properties make it suitable for the synthesis of compounds with pesticidal, herbicidal, or fungicidal activities. The methyl group can be modified to create derivatives with improved efficacy and selectivity against target pests or weeds.
Used in Organic Synthesis:
Pyrimidine, 2-(chloromethyl)-4-methyl(9CI) is also used as a versatile starting material in organic synthesis. Its unique structure and reactivity make it a valuable precursor for the preparation of various organic compounds, including dyes, polymers, and other specialty chemicals. The chloromethyl group can be replaced with other functional groups, allowing for the synthesis of a wide range of derivatives with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 78060-44-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,0,6 and 0 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 78060-44:
(7*7)+(6*8)+(5*0)+(4*6)+(3*0)+(2*4)+(1*4)=133
133 % 10 = 3
So 78060-44-3 is a valid CAS Registry Number.
78060-44-3Relevant academic research and scientific papers
IMIDAZOTRIAZINONE COMPOUNDS
-
Paragraph 0628; 0629, (2013/10/08)
The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.
